Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.

Advertisement

Related Content

With Corlanor Approval, Amgen Kicks Its CV Push Into High Gear
Amgen Positions Ivabradine As A Foot In The Door Ahead Of PCSK9 Launch
Amgen Positions Ivabradine As A Foot In The Door Ahead Of PCSK9 Launch
Biopharma Dealmaking Quarterly Statistics, Q3 2013
Amgen Makes The Case For Growth, Dispenses With Share Buybacks
Servier Offers $483 Million To Buy Rest Of Hungarian Generics Maker Egis
Deals of the Week: Is Botox On The Block?
Onyx Starts Acquisition Process; Price And Competition To Come Into Play
NICE Backing For Procolaran In CHF May Prove Lucrative For Servier
Amgen Elects Option On Cardiac Drug, Improving Cytokinetics' Strong Cash Position

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel